Treaty of Fort Harmar
Treaty of Greenville
Treaty of St. Louis (1804)
Treaty of Portage des Sioux
Treaty of St. Louis (1816)
Treaty of St. Louis (1822)
Treaty of Washington
First Treaty of Prairie du Chien
Fourth Treaty of Prairie du Chien
1832 Treaty
September 27, 1836 Treaty
September 28, 1836 Treaty
September 28, 1836 Treaty
1837 Treaty
1837 Treaty
1842 Treaty
1854 Treaty (Missouri Sac and Fox)
1859 Treaty
1861 Treaty (Iowa Sac and Fox)
Feb 18th, 1867
June 10, 1872 "Act of Congress" (Missouri Sac and Fox)
Feb 13th, 1891 "Act of Congress"

Clan system
The Sauk and Fox peoples were divided into two moieties or "divisions", which in turn were subdivided into Patri-lineages and Clans as local subgroups (segments). The moieties were known as the Kishko/Ki-sko-ha/Kîshkôha (male: Kîshkôha, female: Kîshkôhkwêha) ("the long-haired") and as the Oskush/Askasa/Shkasha (male: Shkasha/Oshkashîwiwa, female: Shkashîhkwêwa/Oshkashîhkwêwiwa) ("the brave"). The two moieties were each symbolized by two colors: The Askasa/Shkasha painted their faces and partly their bodies with charcoal in mahkatêwâwi (black) and the Ki-sko-ha/Kîshkôha painted their bodies with white clay in wâpeshkyâwi (white). This duality was also celebrated by the two moieties in Lacrosse, which was often played extremely brutally to toughen young warriors for combat, for recreation, as part of festivals, and used as preparation for imminent wars or raids. This division has survived to the present day, but is now more related to the political system of the United States: the supporters of the Democratic Party are associated with the Kîshkôha/Kîshkôhkwêha, while the supporters of the Republican Party are associated with the Shkasha/Shkashîhkwêwa.
Betaxolol is a selective beta1 receptor blocker used in the treatment of hypertension and glaucoma. Being selective for beta1 receptors, it typically has fewer systemic side effects than non-selective beta-blockers, for example, not causing bronchospasm (mediated by beta2 receptors) as timolol may. Betaxolol also shows greater affinity for beta1 receptors than metoprolol. In addition to its effect on the heart, betaxolol reduces the pressure within the eye (intraocular pressure). This effect is thought to be caused by reducing the production of the liquid (which is called the aqueous humor) within the eye. The precise mechanism of this effect is not known. The reduction in intraocular pressure reduces the risk of damage to the optic nerve and loss of vision in patients with elevated intraocular pressure due to glaucoma. It was patented in 1975 and approved for medical use in 1983. Medical uses
Oral: for the management of hypertension
Ophthalmic: for the management of glaucoma
the drug seems to have an effect of neuroprotection in glaucoma treatment

Contraindications
Hypersensitivity to the drug
Patients with sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure

Side effects
History
Betaxolol was approved by the U.S. Food and Drug Administration (FDA) for ocular use as a 0.5% solution (Betoptic) in 1985 and as a 0.25% solution (Betoptic S) in 1989. Society and culture
Brand names
Brand names include Betoptic, Betoptic S, Lokren, Kerlone. See also
Levobetaxolol
Cicloprolol

References
External links
Kerlone prescribing information